Switch theme
Sign up to access all valuation multiples
Innovita Biological Technology Co Ltd is a biotechnology company focusing on the research and development, production and sales of POCT in vitro diagnostic products.
2006
n/a
LTM Revenue $124M
LTM EBITDA n/a
$344M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Innovita Biological Tech has a last 12-month revenue of $124M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Innovita Biological Tech achieved revenue of $65.9M and an EBITDA of $30.9M.
Innovita Biological Tech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Innovita Biological Tech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $65.9M | $111M | XXX | XXX | XXX |
| Gross Profit | $34.5M | $37.7M | XXX | XXX | XXX |
| Gross Margin | 52% | 34% | XXX | XXX | XXX |
| EBITDA | $30.9M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 47% | NaN% | XXX | XXX | XXX |
| Net Profit | $16.6M | $20.8M | XXX | XXX | XXX |
| Net Margin | 25% | 19% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Innovita Biological Tech's stock price is CNY 32 (or $4).
Innovita Biological Tech has current market cap of CNY 4.4B (or $600M), and EV of CNY 2.5B (or $344M).
See Innovita Biological Tech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $344M | $600M | XXX | XXX | XXX | XXX | $0.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Innovita Biological Tech has market cap of $600M and EV of $344M.
Innovita Biological Tech's trades at 2.8x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Innovita Biological Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Innovita Biological Tech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $344M | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | 11.0x | XXX | XXX | XXX |
| P/E/Growth | 0.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpInnovita Biological Tech's NTM/LTM revenue growth is 39%
Innovita Biological Tech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Innovita Biological Tech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Innovita Biological Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Innovita Biological Tech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 68% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 31% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Innovita Biological Tech acquired XXX companies to date.
Last acquisition by Innovita Biological Tech was XXXXXXXX, XXXXX XXXXX XXXXXX . Innovita Biological Tech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Innovita Biological Tech founded? | Innovita Biological Tech was founded in 2006. |
| Where is Innovita Biological Tech headquartered? | Innovita Biological Tech is headquartered in China. |
| Is Innovita Biological Tech publicy listed? | Yes, Innovita Biological Tech is a public company listed on SHG. |
| What is the stock symbol of Innovita Biological Tech? | Innovita Biological Tech trades under 688253 ticker. |
| When did Innovita Biological Tech go public? | Innovita Biological Tech went public in 2022. |
| Who are competitors of Innovita Biological Tech? | Similar companies to Innovita Biological Tech include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Innovita Biological Tech? | Innovita Biological Tech's current market cap is $600M |
| What is the current revenue of Innovita Biological Tech? | Innovita Biological Tech's last 12-month revenue is $124M. |
| What is the current EV/Revenue multiple of Innovita Biological Tech? | Current revenue multiple of Innovita Biological Tech is 2.8x. |
| What is the current revenue growth of Innovita Biological Tech? | Innovita Biological Tech revenue growth between 2023 and 2024 was 68%. |
| Is Innovita Biological Tech profitable? | Yes, Innovita Biological Tech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
